**Supplemental Materials**

**Table S1. Baseline patient, angiographic and procedural characteristics according to DAPT duration.**

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | DAPT ≤ 1-year (n=1368) | DAPT > 1-year (n=2989) | P value |
| Age, years | 58 (50-65) | 58 (50-65) | 0.930 |
| Male, n(%) | 1107 (80.9) | 2424 (81.1) | 0.890 |
| Body mass index, kg/m2 | 25.9 (23.7-27.8) | 25.9 (23.9-27.8) | 0.351 |
| Current smoker, n(%) | 832 (60.8) | 1832 (61.3) | 0.766 |
| Diabetes mellitus, n(%) | 553 (40.4) | 1194 (39.9) | 0.765 |
| Hypertension, n(%) | 856 (62.6) | 1862 (62.3) | 0.860 |
| Dyslipidemia, n(%) | 870 (63.6) | 1998 (66.8) | **0.036** |
| Previous myocardial infarction, n(%) | 175 (12.8) | 404 (13.5) | 0.514 |
| Previous PCI, n(%) | 261 (19.1) | 599 (20.0) | 0.459 |
| Previous CABG, n(%) | 51 (3.7) | 109 (3.6) | 0.895 |
| Previous stroke, n(%) | 126 (9.2) | 291 (9.7) | 0.584 |
| Peripheral vascular disease, n(%) | 21 (1.5) | 71 (2.4) | 0.073 |
| Chronic kidney disease, n(%) | 120 (8.8) | 309 (10.3) | 0.107 |
| COPD, n(%) | 38 (2.8) | 67 (2.2) | 0.284 |
| LVEF, % | 64 (60-68) | 64 (60-68) | 0.459 |
| LVEF<50%, n (%) | 57 (4.3) | 113 (3.9) | 0.538 |
| Systolic blood pressure, mmHg | 124 (116-138) | 125 (119-140) | 0.540 |
| Laboratory data |  |  |  |
| WBC, 103/uL | 6.49 (5.54-7.74) | 6.59 (5.55-7.83) | 0.412 |
| Hemoglobin, g/L | 145 (135-156) | 146 (136-155) | 0.458 |
| Total cholesterol, mmol/L | 4.01 (3.43-4.76) | 4.04 (3.43-4.80) | 0.595 |
| LDL-C, mmol/L | 2.32 (1.85-2.98) | 2.36 (1.85-2.99) | 0.672 |
| HDL-C, mmol/L | 1.00 (0.85-1.17) | 0.98 (0.82-1.18) | 0.073 |
| HbA1c, % | 6.2 (5.8-6.8) | 6.2 (5.8-6.9) | 0.321 |
| Lp(a), mg/dL | 17.4 (7.3-37.1) | 17.3 (7.6-38.7) | 0.453 |
| Radial artery access, n(%) | 1294 (94.6) | 2764 (92.5) | **0.010** |
| Multivessel disease, n (%) | 954 (69.7) | 2171 (72.6) | **0.049** |
| SYNTAX score | 9 (6-16) | 9.5 (6-15) | 0.758 |
| SYNTAX score >22, n(%) | 120 (9.0) | 258 (8.9) | 0.884 |
| Total lesion length, mm | 29 (18-48) | 30 (18-48) | 0.346 |
| Target lesion morphology |  |  |  |
| Bifurcation lesion, n(%) | 273 (20.0) | 558 (18.7) | 0.315 |
| 2-stent technique, n(%) | 57 (4.2) | 124 (4.1) | 0.978 |
| Chronic total occlusion, n(%) | 207 (15.1) | 479 (16.0) | 0.452 |
| In-stent restenosis, n(%) | 55 (4.0) | 132 (4.4) | 0.550 |
| Severe calcification, n(%) | 23 (1.7) | 92 (3.1) | **0.008** |
| Angulation > 45 degrees, n(%) | 151 (11.0) | 289 (9.7) | 0.164 |
| Type B2 or C lesion, n(%) | 1032 (75.4) | 2220 (74.3) | 0.412 |
| No. vessels treated | 1 (1-1) | 1 (1-2) | 0.325 |
| No. lesions treated | 1 (1-2) | 1 (1-2) | 0.531 |
| No. lesions treated ≥3, n(%) | 85 (6.2) | 191 (6.4) | 0.824 |
| Drug-eluting stent number | 2 (1-2) | 2 (1-2) | 0.080 |
| Drug-eluting stent number ≥ 3, n(%) | 276 (20.2) | 618 (20.7) | 0.704 |
| Use of EES/ZES, n(%) | 763 (55.8) | 1687 (56.4) | 0.681 |
| Minimum stent diameter, mm | 3.00 (2.50-3.50) | 3.00 (2.50-3.50) | **0.037** |
| Total stent length, mm | 33 (23-52) | 34 (23-52) | 0.553 |
| DAPT score | 2 (1-2) | 2 (1-2) | 0.380 |
| DAPT score≥2, n (%) | 773 (56.5) | 1749 (58.5) | 0.213 |
| Medications at discharge |  |  |  |
| Aspirin, n(%) | 1368 (100) | 2989 (100) | NA |
| P2Y12 receptor inhibitor, n(%) | 1368 (100) | 2989 (100) | NA |
| Oral anticoagulant, n (%) | 4 (0.4) | 4 (0.2) | 0.457 |
| β-blockers, n(%) | 1205 (88.1) | 2644 (88.5) | 0.722 |
| Statins, n(%) | 1312 (95.9) | 2873 (96.1) | 0.738 |
| Calcium channel blockers, n(%) | 688 (50.3) | 1539 (51.5) | 0.463 |
| Antiplatelet drugs at 6 months | n=1368 | n=2989 |  |
| Aspirin, n (%) | 1351 (98.8) | 2989 (100) | **< 0.001** |
| P2Y12 receptor inhibitor, n (%) | 1347 (98.5) | 2989 (100) | **< 0.001** |
| Antiplatelet drugs at 12 months | n=1368 | n=2989 |  |
| Aspirin, n (%) | 1310 (95.8) | 2989 (100) | **< 0.001** |
| P2Y12 receptor inhibitor, n (%) | 1252 (91.5) | 2989 (100) | **< 0.001** |
| Antiplatelet drugs at 18 months | n=1368 | n=2988 |  |
| Aspirin, n (%) | 1254 (91.7) | 2974 (99.5) | **< 0.001** |
| P2Y12 receptor inhibitor, n (%) | 38 (2.8) | 2690 (90.0) | **< 0.001** |
| Antiplatelet drugs at 24 months | n=1367 | n=2976 |  |
| Aspirin, n (%) | 1248 (91.3) | 2916 (98.0) | **< 0.001** |
| P2Y12 receptor inhibitor, n (%) | 32 (2.3) | 1248 (41.9) | **< 0.001** |
| Antiplatelet drugs at 30 months | n=343 | n=1146 |  |
| Aspirin, n (%) | 295 (86.0) | 1124 (98.1) | **< 0.001** |
| P2Y12 receptor inhibitor, n (%) | 9 (2.6) | 334 (29.1) | **< 0.001** |
| DAPT time, days | 349±61 | 661±163 | **< 0.001** |
|  | 365 (365-365) | 548 (548-796) |  |

CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DAPT, dual antiplatelet therapy; EES, everolimus-eluting stent; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; WBC, white blood cell; ZES, zotarolimus-eluting stent.

**Table S2. Two-year clinical outcomes according to Lp(a) levels and DAPT duration.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Clinical endpoint | DAPT ≤ 1-year, n(%) | DAPT > 1-year, n(%) | Crude HR(95% CI) | Multivariable adjusted HR(95% CI) | IPTW adjusted HR(95% CI) |
| **Cardiac death/MI/stroke** |  |  |  |  |  |
| Overall population | 31 (2.3) | 39 (1.3) | **0.561 (0.349-0.901)** | **0.559 (0.333-0.940)** | **0.569 (0.354-0.916)** |
| Lp(a) ≤ 30mg/dl | 19 (2.0) | 27 (1.3) | 0.640 (0.355-1.153) | 0.736 (0.374-1.449) | 0.653 (0.363-1.174) |
| Lp(a) > 30mg/dl | 12 (2.7) | 12 (1.2) | **0.425 (0.191-0.948)** | **0.284 (0.115-0.700)** | **0.436 (0.195-0.978)** |
| **All-cause death** |  |  |  |  |  |
| Overall population | 31 (2.3) | 5 (0.2) | **0.070 (0.027-0.179)** | **0.061 (0.021-0.176)** | **0.072 (0.028, 0.187)** |
| Lp(a) ≤ 30mg/dl | 23 (2.5) | 2 (0.1) | **0.038 (0.009-0.162)** | **0.021 (0.003-0.159)** | **0.037 (0.009-0.160)** |
| Lp(a) > 30mg/dl | 8 (1.8) | 3 (0.3) | **0.156 (0.041-0.591)** | **0.061 (0.010-0.369)** | **0.184 (0.047-0.723)** |
| **Cardiac death** |  |  |  |  |  |
| Overall population | 14 (1.0) | 3 (0.1) | **0.093 (0.027-0.325)** | **0.081 (0.019-0.337)** | **0.096 (0.027, 0.337)** |
| Lp(a) ≤ 30mg/dl | 9 (1.0) | 0 (0) | NA | NA | NA |
| Lp(a) > 30mg/dl | 5 (1.1) | 3 (0.3) | 0.253 (0.060-1.063) | **0.103 (0.016-0.677)** | 0.283 (0.064-1.245) |
| **Non-fatal MI** |  |  |  |  |  |
| Overall population | 7 (0.5) | 14 (0.5) | 0.866 (0.349-2.150) | 0.715 (0.262-1.955) | 0.838 (0.331-2.120) |
| Lp(a) ≤ 30mg/dl | 4 (0.4) | 6 (0.3) | 0.681 (0.192-2.414)  | 0.549 (0.120-2.510) | 0.661 (0.184-2.377) |
| Lp(a) > 30mg/dl | 3 (0.7) | 8 (0.8) | 1.094 (0.290-4.135) | 0.677 (0.158-2.900) | 1.089 (0.277-4.279) |
| **Stroke** |  |  |  |  |  |
| Overall population | 15 (1.1) | 25 (0.8) | 0.760 (0.399-1.450) | 0.766 (0.384-1.528) | 0.782 (0.441-1.486) |
| Lp(a) ≤ 30mg/dl | 9 (1.0) | 21 (1.0) | 1.056 (0.482-2.314) | 1.211 (0.501-2.926) | 1.095 (0.507-2.365) |
| Lp(a) > 30mg/dl | 6 (1.4) | 4 (0.4) | 0.295 (0.083-1.046) | **0.188 (0.041-0.861)** | 0.311 (0.087-1.106) |
| **Definite/probable ST** |  |  |  |  |  |
| Overall population | 15 (1.1) | 7 (0.2) | **0.202 (0.082-0.496)** | **0.192 (0.069-0.539)** | **0.207 (0.084-0.509)** |
| Lp(a) ≤ 30mg/dl | 10 (1.1) | 3 (0.1) | **0.136 (0.037-0.494)** | **0.121 (0.024-0.618)** | **0.135 (0.037-0.495)** |
| Lp(a) > 30mg/dl | 5 (1.1) | 4 (0.4) | 0.326 (0.087-1.219) | **0.167 (0.033-0.836)** | 0.368 (0.097-1.394) |
| **BARC type 2, 3, or 5 bleeding** |  |  |  |  |  |
| Overall population | 19 (1.4) | 28 (0.9) | 0.671(0.374-1.203) | 0.620 (0.335-1.148) | 0.725 (0.404-1.302) |
| Lp(a) ≤ 30mg/dl | 9 (1.0) | 16 (0.8) | 0.813 (0.359-1.839) | 0.688 (0.293-1.612) | 0.869 (0.382-1.977) |
| Lp(a) > 30mg/dl | 10 (2.3) | 12 (1.2) | 0.579 (0.244-1.375) | 0.630 (0.245-1.621) | 0.621 (0.257-1.500) |

BARC, Bleeding Academic Research Consortium; CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weighting; MI, myocardial infarction; ST, stent thrombosis.

**Figure S1.** Kaplan–Meier curves for 2.4-year clinical outcomes according to DAPT duration in patients with (A) Lp(a) levels > 30mg/dl and (B) Lp(a) levels ≤ 30mg/dl, respectively. BARC, Bleeding Academic Research Consortium; DAPT, dual antiplatelet therapy; MI, myocardial infarction; ST, stent thrombosis



